Inactive Instrument

News Interpace Diagnostics Group Inc Nasdaq

Equities

US46062X1054

End-of-day quote Nasdaq Other stock markets
- ^USD	-

03-07	Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M	MT
03-07	Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M	03-07	MT
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results	03-07	AQ
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07	CI
Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board?s Regulatory Compliance Committee	12-12	CI
Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director	11-16	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results	11-08	AQ
Interpace Biosciences, Inc. Enters Amendment to Loan Security Agreement with Broadoak Fund V, L.P	23-10-27	CI
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results	23-08-09	AQ
Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Chief Financial Officer	23-08-02	CI
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement	23-07-10	AQ
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023	23-06-05	AQ
Interpace Biosciences, Inc. Expects to Stop Offering Pancragen Test Due to CMS Decision to End Reimbursement as of July 17, 2023	23-06-05	CI
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q1 Revenue $9.8M	23-05-12	MT
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results	23-05-12	AQ
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Principal Financial Officer	23-04-25	CI
INTERPACE BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)	23-04-25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Interpace Diagnostics Group Inc Nasdaq

Equities

US46062X1054

Summary

Filters